1. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?;Abahssain;Journal of Oncology Pharmacy Practice,2021
2. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue;Aeschlimann;Drug Metabolism and Disposition,1996
3. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy;Aeschlimann;Drug Metabolism and Disposition,1998
4. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide;Alarcon;Cancer Research,1972
5. Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878));Albo;Cancer Chemotherapy Reports,1975